Opinion · VigiEye View Pharmacovigilance

Safety judgment belongs apart from the product line, and CBER just said so

FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.

VigiEye editorial · Fri 20 Nov 2026

A structural signal, not a procedural footnote

On 19 November, FDA created the CBER Safety Council to oversee postmarket safety of biologics. It replaces the Safety Working Group, sits apart from the product offices and reports directly to the Center Director. The records give us nothing on its powers, its membership or how it will deal with sponsors, and I won't guess. The design, though, is plain: when safety is overseen by a body separate from the offices that own the products, the agency is saying that independence of judgment is itself a control.

My position is that QPPVs and PV leaders should read this as a prompt to audit their own governance, not as someone else's reorganisation. If a regulator concludes that postmarket safety needs distance from product-level decision-making, no marketing authorisation holder should assume its own arrangements are beyond question.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this column is based on

Opinion: this column argues a position. Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →